Avidity Biosciences

Avidity Biosciences is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs), a new class of RNA therapeutics designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies. The company is leading clinical development programs for rare muscle diseases including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy, with an expanding pipeline in cardiology and immunology.